The online version of this article (doi:10.1007/s40120-014-0020-y) contains supplementary material, which is available to authorized users.
Teriflunomide, indicated for the treatment of relapsing–remitting multiple sclerosis, is contraindicated in pregnancy based on signs of developmental toxicity in the offspring of rats and rabbits; developmental toxicity has also been observed in preclinical studies of other disease-modifying therapies. Despite the requirement to use reliable contraception in clinical trials evaluating the safety and efficacy of teriflunomide, a number of pregnancies have been reported. This work reports pregnancy outcomes in teriflunomide clinical trials.
Pregnancy outcomes were evaluated in a retrospective analysis of the global pharmacovigilance database. The following information was collected from the pharmacovigilance database or individual patient files: treatment allocation, pregnancy outcome, teriflunomide exposure, and use of the accelerated elimination procedure.
At data cut-off, 83 pregnancies were reported in female patients and 22 pregnancies were documented in partners of male patients. All newborns were healthy and did not have any structural or functional abnormalities at birth.
Available data do not indicate any teratogenic signals in patients treated with teriflunomide.
Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler J. 2013;19:835–43. CrossRef
AUBAGIO prescribing information. Cambridge: Genzyme Corporation, a Sanofi company; 2012. Available from: http://products.sanofi.us/aubagio/aubagio.pdf. Accessed Aug 28, 2014.
AUBAGIO Summary of Product Characteristics. Paris: Sanofi-aventis groupe; 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002514/WC500148682.pdf. Accessed Aug 28, 2014.
ARAVA prescribing information. Bridgewater: Sanofi-aventis U.S. LLC; 2014. Available from: http://products.sanofi.us/arava/arava.html. Accessed Aug 28, 2014.
Organization of Teratology Information Specialists (OTIS). MotherToBaby. Available from: www.pregnancystudies.org. Accessed Oct 31, 2014.
- Pregnancy Outcomes Following Maternal and Paternal Exposure to Teriflunomide During Treatment for Relapsing–Remitting Multiple Sclerosis
Bernd C. Kieseier
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II